Hangzhou Tigermed Consulting Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St · 08/31 01:03

Hangzhou Tigermed Consulting (SZSE:300347) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥1.70b (down 11% from 2Q 2023).
  • Net income: CN¥257.8m (down 69% from 2Q 2023).
  • Profit margin: 15% (down from 43% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
  • EPS: CN¥0.30 (down from CN¥0.95 in 2Q 2023).
earnings-and-revenue-growth
SZSE:300347 Earnings and Revenue Growth August 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hangzhou Tigermed Consulting Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 40%.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China.

Performance of the Chinese Life Sciences industry.

The company's shares are up 6.8% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Hangzhou Tigermed Consulting you should know about.